8-K: Salarius Pharmaceuticals Faces Nasdaq Delisting Due to Low Bid Price and Equity Standard Non-Compliance

Salarius Pharmaceuticals receives notice from Nasdaq regarding non-compliance with minimum bid price and equity standards, potentially leading to delisting.

Summary

• Salarius Pharmaceuticals received a delisting notice from Nasdaq on April 23, 2025, due to non-compliance with the minimum bid price requirement of $1.00 per share.
• The company is ineligible for a compliance period because it executed a reverse stock split within the past year.
• Salarius also failed to meet the minimum stockholders' equity requirement of $2.5 million.
• Nasdaq will not entertain a compliance plan due to the bid price deficiency.
• The company intends to appeal the delisting determination by April 30, 2025.
• The appeal will stay the suspension of trading and the filing of Form 25-NSE pending a decision from the Nasdaq Hearings Panel.
• Salarius plans to present its strategy to regain compliance in connection with its planned merger with Decoy Therapeutics Inc.
• There is no guarantee that the Hearings Panel will rule favorably or that the company's securities will remain listed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance with Nasdaq listing requirements. The planned merger offers some hope, but its success is not guaranteed.

Positives

• The company intends to appeal the delisting determination, which will temporarily prevent the suspension of its securities.
• Salarius plans to present its plans to regain compliance with Nasdaq listing requirements in connection with its planned merger transaction with Decoy Therapeutics Inc.

Negatives

• The company received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement.
• Salarius is not eligible for a compliance period due to a prior reverse stock split.
• The company also failed to meet the minimum stockholders' equity requirement.
• Nasdaq will not entertain a compliance plan due to the bid price deficiency.
• There is no assurance that the Hearings Panel will rule favorably or that the company's securities will remain listed.

Risks

• The company faces the risk of delisting from The Nasdaq Capital Market.
• There is no guarantee that the company will regain compliance with Nasdaq's listing requirements.
• The planned merger with Decoy Therapeutics Inc. may not be completed.
• The company's stock price may be negatively impacted by the delisting notice.

Future Outlook

The company plans to appeal the delisting determination and present its plans to regain compliance with Nasdaq listing requirements in connection with its planned merger with Decoy Therapeutics Inc. However, there is no assurance that the Hearings Panel will rule favorably or that the company's securities will remain listed.

Management Comments

• The Company intends to present its plans to regain compliance with the Minimum Bid Price Requirement and the Equity Standard in connection with the Company's planned merger transaction with Decoy Therapeutics Inc.

Industry Context

Delisting notices are not uncommon for small-cap pharmaceutical companies, especially those undergoing significant changes or facing financial challenges. Other companies in similar situations may explore reverse stock splits, mergers, or other strategic alternatives to maintain their listing.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq listing compliance, especially during periods of market volatility or when facing clinical trial setbacks.
• Reverse stock splits are a common, though often viewed negatively, tactic used by companies to boost their share price and avoid delisting; however, Nasdaq rules limit their effectiveness if used repeatedly.
• Mergers and acquisitions can provide a pathway to regaining compliance by strengthening the balance sheet and improving market capitalization, but the success of such strategies is not guaranteed.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty regarding their job security.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• The company will request an appeal of the delisting determination by April 30, 2025.
• The company will present its plans to regain compliance with Nasdaq listing requirements to the Hearings Panel.
• The company will continue to pursue its planned merger with Decoy Therapeutics Inc.

Key Dates

Keywords

delisting, Nasdaq, compliance, minimum bid price, stockholders' equity, appeal, merger, Decoy Therapeutics, Salarius Pharmaceuticals